After Flovent, a popular inhaler for childhood asthma, was discontinued in January, some parents are facing challenges in obtaining the generic versions of the medication. Both versions of the inhaler are identical and manufactured by the same pharmaceutical company, GSK, based in London. The company has announced that it will discontinue manufacturing the branded Flovent HFA and Flovent Diskus for the U.S. market, effective January 1, 2024.
The transition from the branded to the generic version of Flovent is expected to have minimal disruption for patients, according to GSK. Most insurance plans will likely replace Flovent with a generic version, but patients may experience delays if their insurance does not cover the generic. The Asthma and Allergy Foundation of America (AAFA) advises patients to request a “formulary exception” if their insurance plan does not cover the generic fluticasone.
The switch from brand name to generic versions of medications can often result in lower prices for consumers due to increased competition among multiple manufacturers. However, insurance coverage plays a significant role in determining the actual cost to patients. Some customers may see large price discrepancies if their insurance only covers a different generic inhaler and not generic Flovent.
The switch to generic versions of inhalers may also involve changes in the type of device used. Meter dose inhalers (MDIs) and dry powder inhalers (DPIs) are two common types of inhalers, and they are not used in the same way. MDIs spray a pre-set amount of medicine into the airway, while DPIs require patients to adequately breathe in the medicine. The type of device and medicine can impact effectiveness on individual patients.
Looking ahead, the discontinuation of branded medications in favor of generics is likely to continue as a way to create lower prices for consumers. However, ensuring insurance coverage for generic medications and understanding the implications of device changes will remain important considerations for patients and healthcare providers.
In the current healthcare landscape, the complexities of the drug pricing ecosystem and the roles of drug manufacturers, pharmacy benefit managers, insurance companies, employers, and federal policies can create situations that reduce access to critical medications. As the industry evolves, it will be essential for stakeholders to work together to address these issues and ensure that patients have timely access to affordable and effective treatments.
Overall, the discontinuation of Flovent and the transition to generic versions highlight the need for ongoing discussions and solutions to improve drug pricing, insurance coverage, and patient access to essential medications. Healthcare stakeholders should prioritize patient well-being and develop strategies that promote affordability, availability, and quality care. By addressing these challenges, the industry can better serve patients and contribute to a healthier society.
